This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Tadalafil: Difference between revisions
>Espaim m removed reference with invalid doi |
>Lilylunatic Added proper citation for the introduction paragraph and treated conditions |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{headerpanel|{{Approval}}}} | |||
{{stub}} | {{stub}} | ||
{{references}} | {{references}} | ||
| Line 4: | Line 5: | ||
{{SubstanceBox/Tadalafil}} | {{SubstanceBox/Tadalafil}} | ||
'''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED).<ref>{{cite web|url=https://www. | '''Tadalafil''' is a phosphodiesterase type 5 (PDE5) inhibitor marketed under the trade name '''Cialis''' primarily used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and Pulmonary Arterial Hypertension (PAH).<ref name="hahappbig">{{cite web | last=Fahmy | first=George | last2=Hess | first2=Jaclyn | title=Tadalafil | publisher=StatPearls Publishing | date=2024-03-20 | pmid=38753929 | url=https://www.ncbi.nlm.nih.gov/books/NBK603743/ | access-date=2024-10-09}}</ref> It is a post-synaptic [[agonist]] of the cGMP-specific phosphodiesterase type 5 (PDE5) enzyme, preventing cGMP breakdown and enhancing smooth muscle relaxation in the corpus cavernosum of the penis.<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/en/documents/product-information/cialis-epar-product-information_en.pdf|title=Cialis: EPAR Product Information|publisher=European Medicines Agency (EMA)|access-date=January 24, 2023}}</ref> | ||
[[File:Tadalafil_structure.png|thumb|Chemical Structure of Tadalafil]] | [[File:Tadalafil_structure.png|thumb|Chemical Structure of Tadalafil]] | ||